Nuevocor, a biotechnology company that develops therapies for cardiomyopathies, has appointed Monica Shah, MD, as chief medical officer.
Dr. Shah is a heart failure and transplant cardiologist with more than 20 years of experience in cardiovascular medicine and drug development, according to an April 28 news release from Nuevocor.
In the role, Dr. Shah will lead Nuevocor’s global clinical development and medical affairs. The company is currently preparing to initiate a first-in-human clinical study of NVC-001 in patients with LMNA-associated dilated cardiomyopathy, the release said.
Dr. Shah most recently served as chief medical officer of CTI Clinical Trial & Consulting, overseeing medical strategy across clinical programs including rare disease, gene therapy and cardiovascular indications, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
